Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: EST001
MIFTS: 49

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

About this section

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060075
Sources

Summaries for Estrogen-Receptor Positive Breast Cancer

About this section
Disease Ontology : 12 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to mammographic density and tubular adenocarcinoma. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Palbociclib and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Estrogen-Receptor Positive Breast Cancer

About this section

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 mammographic density 31.2 PGR ESR1 CYP19A1
2 tubular adenocarcinoma 31.0 PGR ESR1 ERBB2 EGFR
3 cribriform carcinoma 31.0 PGR ESR1 ERBB2
4 vaginal discharge 30.9 PGR ESR1 CYP19A1
5 endometrial disease 30.9 PGR ESR1 CYP19A1
6 vaginitis 30.9 ESR2 ESR1 AR
7 postmenopausal atrophic vaginitis 30.9 ESR2 ESR1 CYP19A1
8 papillary adenocarcinoma 30.8 TP53 PGR ERBB2 BRCA1
9 fallopian tube carcinoma 30.5 TP53 PGR MYC ESR1 ERBB2 BRCA1
10 mucinous adenocarcinoma 30.4 TP53 PGR ESR2 ESR1 ERBB2 EGFR
11 exanthem 30.3 MTOR ERBB2 EGFR AKT1
12 estrogen-receptor negative breast cancer 30.3 SRC PGR FOXA1 ESR1 ERBB2 EGFR
13 endometrial hyperplasia 30.3 TP53 PGR NCOA3 MTOR ESR2 ESR1
14 hypertrophy of breast 30.2 TP53 PIK3CA PGR ESR1 ERBB2 EGFR
15 female breast cancer 30.2 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
16 tuberous sclerosis 30.2 TP53 PIK3CA MYC MTOR AKT1
17 breast disease 30.1 TP53 PGR MIR125A ESR2 ESR1 ERBB2
18 adenocarcinoma 29.9 TP53 PIK3CA MYC ERBB2 EGFR CCND1
19 breast ductal carcinoma 29.8 TP53 PGR ESR2 ESR1 ERBB2 EGFR
20 sporadic breast cancer 29.7 TP53 PGR MYC ESR2 ESR1 ERBB2
21 osteoporosis 29.7 TP53 SRC PGR ESR2 ESR1 CYP19A1
22 thymoma 29.6 TP53 PIK3CA MTOR MIR125A EGFR CCND1
23 breast adenocarcinoma 29.6 TP53 PIK3CA PGR MYC MTOR ESR1
24 in situ carcinoma 29.5 TP53 PIK3CA PGR MYC ESR1 ERBB2
25 body mass index quantitative trait locus 11 29.3 TP53 SRC NCOA3 MTOR MIR125A ESR1
26 ductal carcinoma in situ 29.1 TP53 PIK3CA PGR MYC ESR2 ESR1
27 breast cancer 28.9 TP53 SRC PIK3CA PGR NCOA3 MYC
28 hepatocellular carcinoma 28.6 TP53 SRC PIK3CA MYC MTOR MIR125A
29 lung cancer susceptibility 3 28.5 TP53 SRC PIK3CA MYC MTOR MIR125A
30 endometrial cancer 28.5 TP53 PIK3CA PGR NCOA3 MYC MTOR
31 esophageal leukoplakia 10.7 TP53 CCND1
32 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1
33 chronic tympanitis 10.7 PGR ESR1
34 granulomatous endometritis 10.7 PGR ESR1
35 rare head and neck tumor 10.7 TP53 PIK3CA
36 uterine corpus adenosarcoma 10.7 PGR ESR1
37 liver adenomatosis 10.7 PGR AR
38 vaginal glandular tumor 10.7 PGR ESR1
39 scirrhous adenocarcinoma 10.6 PGR ERBB2
40 glassy cell carcinoma of the cervix 10.6 PGR ESR1 ERBB2
41 bartholin's gland adenoma 10.6 TP53 PGR ESR1
42 bartholin's gland benign neoplasm 10.6 TP53 PGR ESR1
43 vestibular gland benign neoplasm 10.6 TP53 PGR ESR1
44 pancreatic foamy gland adenocarcinoma 10.6 TP53 CCND1
45 lung leiomyoma 10.6 PGR ESR1
46 vulvar syringoma 10.6 PGR ESR1
47 synchronous bilateral breast carcinoma 10.6 PGR BRCA1
48 ovarian seromucinous carcinoma 10.6 TP53 PGR ESR1
49 endometrial squamous cell carcinoma 10.6 TP53 PGR
50 trigonitis 10.6 PGR ESR1

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer
Sources

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

About this section

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

26 (show all 48)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.9 FOXA1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.9 MTOR
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 10.9 FOXA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.9 BRCA1 FOXA1 PIK3CA
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 10.9 CCND1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 10.9 FOXA1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-135 10.9 BRCA1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 10.9 FOXA1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.9 ERBB2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.9 PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.9 CCND1 FOXA1 MTOR PIK3CA AKT1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.9 CCND1 ERBB2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.9 PIK3CA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.9 MTOR MYC
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.9 CCND1 FOXA1 PIK3CA AKT1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.9 CCND1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 10.9 BRCA1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.9 PIK3CA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-199 10.9 CCND1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 10.9 FOXA1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.9 CCND1 FOXA1 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 10.9 CCND1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.9 FOXA1 MTOR PIK3CA AKT1
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.9 BRCA1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.9 PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.9 BRCA1 AKT1
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.9 BRCA1 CCND1 FOXA1 MTOR PIK3CA
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.9 BRCA1
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.9 BRCA1
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.9 MTOR MYC
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.9 AKT1
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.9 CCND1
33 Decreased viability GR00055-A-1 10.47 EGFR MTOR PIK3CA
34 Decreased viability GR00055-A-2 10.47 EGFR MTOR PIK3CA
35 Decreased viability GR00107-A-1 10.47 HSPB8
36 Decreased viability GR00221-A-1 10.47 AKT1 EGFR ESR1 HSPB8 MTOR MYC
37 Decreased viability GR00221-A-2 10.47 AKT1 ESR1 PIK3CA
38 Decreased viability GR00221-A-3 10.47 AKT1 MYC ERBB2
39 Decreased viability GR00221-A-4 10.47 AKT1 EGFR ESR1 HSPB8 MTOR PIK3CA
40 Decreased viability GR00249-S 10.47 AKT1 MYC
41 Decreased viability GR00301-A 10.47 HSPB8
42 Decreased viability GR00342-S-1 10.47 MTOR
43 Decreased viability GR00342-S-2 10.47 MTOR
44 Decreased viability GR00386-A-1 10.47 ESR1
45 Decreased viability GR00402-S-2 10.47 ESR1 MYC PIK3CA
46 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
47 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
48 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
2 behavior/neurological MP:0005386 10.53 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
3 endocrine/exocrine gland MP:0005379 10.52 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
4 cardiovascular system MP:0005385 10.5 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
5 growth/size/body region MP:0005378 10.49 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
6 homeostasis/metabolism MP:0005376 10.49 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
7 immune system MP:0005387 10.48 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
8 integument MP:0010771 10.44 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
9 mortality/aging MP:0010768 10.42 AKT1 AR BRCA1 CCND1 EGFR ERBB2
10 adipose tissue MP:0005375 10.41 AKT1 AR BRCA1 CYP19A1 EGFR ESR1
11 embryo MP:0005380 10.41 AKT1 AR BRCA1 EGFR ERBB2 ESR1
12 hematopoietic system MP:0005397 10.41 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
13 digestive/alimentary MP:0005381 10.38 AR BRCA1 CCND1 CYP19A1 EGFR ERBB2
14 muscle MP:0005369 10.35 AKT1 AR BRCA1 CYP19A1 EGFR ERBB2
15 neoplasm MP:0002006 10.33 AKT1 AR BRCA1 CCND1 EGFR ERBB2
16 nervous system MP:0003631 10.31 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
17 limbs/digits/tail MP:0005371 10.22 AR BRCA1 EGFR ERBB2 ESR1 ESR2
18 craniofacial MP:0005382 10.21 AR CCND1 EGFR ERBB2 MYC NCOA3
19 normal MP:0002873 10.21 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
20 liver/biliary system MP:0005370 10.16 AKT1 AR CYP19A1 EGFR ESR1 ESR2
21 hearing/vestibular/ear MP:0005377 10.05 CYP19A1 EGFR ESR2 MYC NCOA3 TP53
22 reproductive system MP:0005389 10.03 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
23 no phenotypic analysis MP:0003012 10.01 EGFR ESR1 ESR2 MTOR MYC PGR
24 renal/urinary system MP:0005367 9.91 AR BRCA1 CYP19A1 EGFR ESR1 ESR2
25 pigmentation MP:0001186 9.87 AR BRCA1 CYP19A1 EGFR MYC SRC
26 respiratory system MP:0005388 9.7 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
27 skeleton MP:0005390 9.53 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
Sources

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

About this section

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Palbociclib Approved, Investigational Phase 4 571190-30-2 5005498 11431660 5330286
2
Epirubicin Approved Phase 4 56420-45-2 41867
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
5
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
6 Anti-Bacterial Agents Phase 4
7 Antibiotics, Antitubercular Phase 4
8 Alkylating Agents Phase 4
9
Testosterone Approved, Experimental, Investigational Phase 3 58-22-0, 481-30-1 10204 6013
10
Fluorouracil Approved Phase 3 51-21-8 3385
11
Norepinephrine Approved Phase 3 51-41-2 439260
12
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
13
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
14
Metformin Approved Phase 3 657-24-9 14219 4091
15
Goserelin Approved Phase 3 65807-02-5 5311128 47725
16
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
17
Sodium citrate Approved, Investigational Phase 3 68-04-2
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
20
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
21
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
22
Lenograstim Approved, Investigational Phase 3 135968-09-1
23
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
24
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
25
Exemestane Approved, Investigational Phase 2, Phase 3 107868-30-4 60198
26
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
27
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
28
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
29
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
30
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
32
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 5280795 6221
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
34 Neurotransmitter Agents Phase 3
35 Omega 3 Fatty Acid Phase 3
36 Androgens Phase 3
37 Analgesics Phase 3
38 Dopamine Agents Phase 3
39 Duloxetine Hydrochloride Phase 3
40 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
41 Mitogens Phase 3
42 Hormone Antagonists Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Estrogen Receptor Antagonists Phase 3
45 Hormones Phase 3
46 Estrogen Antagonists Phase 3
47 Estrogens Phase 3
48 Aromatase Inhibitors Phase 3
49 Protein Kinase Inhibitors Phase 3
50 Antirheumatic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial Not yet recruiting NCT04137640 Phase 4 palbociclib combined with letrozole;epirubicin combined with cyclophosphamide and sequential docetaxel
3 A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer. Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
4 ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
5 Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias Completed NCT01573442 Phase 3 testosterone
6 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
7 Ovarian Protection Trial In Premenopausal Breast Cancer Patients [OPTION] Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
8 A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
9 A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Completed NCT00265759 Phase 3 anastrozole;exemestane;letrozole
10 A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer Completed NCT01598298 Phase 3 duloxetine hydrochloride
11 S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III Completed NCT01385137 Phase 3
12 A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
13 Efficacy, Tolerability, and Safety of Palbociclib Combined With an Aromatase Inhibitor in Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Locally Advanced Breast Cancer Recruiting NCT04047758 Phase 3 Palbociclib + Letrozole;Letrozole
14 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
15 A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE) Active, not recruiting NCT02482753 Phase 3 Chidamide;exemestane;placebo
16 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
17 International Breast Cancer Intervention Study Active, not recruiting NCT00078832 Phase 3 anastrozole;placebo
18 A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
19 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
20 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
21 A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
22 A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
23 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer Active, not recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
24 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
25 A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Active, not recruiting NCT01349322 Phase 3
26 Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B) Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
27 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
28 MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
29 A Randomized Controlled Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） Enrolling by invitation NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
30 Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
31 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
32 Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients Terminated NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
33 A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer Unknown status NCT02910050 Phase 2 Bicalutamide;Aromatase Inhibitor
34 A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen Unknown status NCT01124695 Phase 2 tamoxifen citrate
35 Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
36 Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients Unknown status NCT00954135 Phase 2 letrozolo+cyclophosphamide;letrozolo+sorafenib+cyclophosphamide
37 A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer Unknown status NCT01142401 Phase 2 Bortezomib;Fulvestrant
38 Randomised Phase II Study of Metronomic Chemotherapy Plus the Same Aromatase Inhibitor Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF and VEGFR Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
39 Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer. Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
40 Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
41 A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI) Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
42 A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0). Completed NCT00093002 Phase 2 Fulvestrant
43 A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
44 A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor Completed NCT00676663 Phase 2 entinostat;exemestane;Placebo
45 Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
46 A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients Completed NCT01605396 Phase 2 Ridaforolimus;Dalotuzumab;Exemestane
47 Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy. Completed NCT02015559 Phase 2 mucoadhesive oral wound rinse
48 Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed NCT02988986 Phase 2 TAK-228;Tamoxifen
49 A Single-arm Phase II Trial to Evaluate Serum Estradiol Levels in Patients With Breast Cancer Treated With Vaginal Estrogen, Estring Completed NCT01923298 Phase 2 Estradiol
50 A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

About this section
Sources

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

About this section

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

40
Breast, Bone, Lymph Node, Testes, Endothelial, Brain, Liver
Sources

Publications for Estrogen-Receptor Positive Breast Cancer

About this section

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 1233)
# Title Authors PMID Year
1
FRET mechanism between a fluorescent breast-cancer drug and photodynamic therapy sensitizers. 61
32470814 2020
2
TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway. 61
32415497 2020
3
DC-SCRIPT affects mammary organoids branching morphogenesis by modulating the FGFR1-pERK signaling axis. 61
32422143 2020
4
Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits. 61
32430459 2020
5
High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. 61
32304412 2020
6
Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: An in vitro study. 61
32530119 2020
7
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells. 61
31177399 2020
8
Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence. 61
32139273 2020
9
Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer. 61
31757843 2020
10
Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. 61
32572715 2020
11
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report. 61
32541460 2020
12
Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application. 61
32166756 2020
13
Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer. 61
31403177 2020
14
Group testing in mediation analysis. 61
32363646 2020
15
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. 61
31805393 2020
16
Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. 61
32433283 2020
17
High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. 61
32370060 2020
18
The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane. 61
31891807 2020
19
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. 61
32430040 2020
20
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. 61
31937617 2020
21
Race May Not Impact Endocrine Therapy-Related Changes in Breast Density. 61
32098892 2020
22
A case of a trans-masculine patient receiving testosterone with a history of estrogen receptor-positive breast cancer. 61
32255524 2020
23
Obesity-Altered Adipose Stem Cells Promote Radiation Resistance of Estrogen Receptor Positive Breast Cancer through Paracrine Signaling. 61
32326381 2020
24
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. 61
32245900 2020
25
Radiogenomics of magnetic resonance imaging and a new multi-gene classifier for predicting recurrence prognosis in estrogen receptor-positive breast cancer: A preliminary study. 61
32311939 2020
26
Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer. 61
31669266 2020
27
Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer. 61
31942683 2020
28
Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care? 61
32125557 2020
29
Ret Receptor Has Distinct Alterations and Functions in Breast Cancer. 61
32080788 2020
30
Thermophoretic Detection of Exosomal microRNAs by Nanoflares. 61
32134270 2020
31
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. 61
32220884 2020
32
Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187. 61
32198343 2020
33
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. 61
31469414 2020
34
Distinguishing metastatic triple-negative breast cancer from nonmetastatic breast cancer using second harmonic generation imaging and resonance Raman spectroscopy. 61
32219996 2020
35
Association between perceived benefits and receipt of radiotherapy among older breast cancer patients. 61
31478585 2020
36
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. 61
31932695 2020
37
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. 61
31811505 2020
38
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. 61
31518174 2020
39
Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study. 61
31918322 2020
40
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy. 61
32309212 2020
41
Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. 61
31733575 2020
42
Association between low estrogen receptor positive breast cancer and staining performance. 61
32047851 2020
43
MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. 61
31963297 2020
44
Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. 61
32064155 2020
45
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer. 61
31721572 2020
46
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? 61
31690650 2020
47
Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment. 61
31646389 2020
48
Synthesis, Cytotoxicity and Antimicrobial Evaluation of New Coumarin-Tagged β-Lactam Triazole Hybrid. 61
31788939 2020
49
Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. 61
31710162 2020
50
Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells. 61
32321078 2020
Sources

Variations for Estrogen-Receptor Positive Breast Cancer

About this section
Sources

Expression for Estrogen-Receptor Positive Breast Cancer

About this section
Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.
Sources

Pathways for Estrogen-Receptor Positive Breast Cancer

About this section

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.31 TP53 SRC PIK3CA PGR NCOA3 MYC
2
ERK Signaling 63
Show member pathways
 13.97 TP53 SRC MYC MTOR ESR2 ESR1
3
Gene Expression 65
Show member pathways
 13.94 TP53 PGR MYC MTOR ESR2 ESR1
4
GPCR Pathway 63
Show member pathways
 13.85 TP53 SRC NCOA3 MYC ESR2 ESR1
5
TGF-Beta Pathway 63
Show member pathways
 13.68 TP53 SRC PIK3CA MYC MTOR ERBB2
6
Akt Signaling 63
Show member pathways
 13.54 TP53 SRC MTOR ERBB2 EGFR CCND1
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.49 TP53 SRC PIK3CA MYC ERBB2 EGFR
8
IL-2 Pathway 63
Show member pathways
 13.36 TP53 SRC MYC MTOR ERBB2 EGFR
9
GAB1 signalosome 65
Show member pathways
 13.25 TP53 SRC PIK3CA MTOR ERBB2 EGFR
10
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.2 TP53 SRC PIK3CA MYC EGFR CCND1
11
PI3K-Akt signaling pathway 36
Show member pathways
 13.13 TP53 PIK3CA MYC MTOR ERBB2 EGFR
12
Human cytomegalovirus infection 36
Show member pathways
 13.11 TP53 SRC PIK3CA MYC MTOR EGFR
13
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.04 SRC PIK3CA MTOR ERBB2 EGFR AKT1
14
Focal Adhesion 36 1
Show member pathways
 13.04 SRC PIK3CA ERBB2 EGFR CCND1 AKT1
15
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13 SRC PIK3CA MTOR ERBB2 EGFR AKT1
16
Endometrial cancer 36
Show member pathways
 13 TP53 SRC PIK3CA MYC MTOR ERBB2
17
Measles 36
Show member pathways
 12.92 TP53 PIK3CA MYC CCND1 AKT1
18
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.91 TP53 SRC PIK3CA MTOR ERBB2 EGFR
19
Herpes simplex virus 1 infection 36
12.9 TP53 SRC PIK3CA MTOR AKT1
20
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.89 PIK3CA MYC MTOR CCND1 AKT1
21
Development HGF signaling pathway 22
Show member pathways
 12.89 TP53 SRC PIK3CA MTOR ESR1 ERBB2
22
MAPK signaling pathway 36 1
12.87 TP53 MYC ERBB2 EGFR AKT1
23
Pathways in cancer 36
12.87 TP53 PIK3CA NCOA3 MYC MTOR ESR2
24
Chks in Checkpoint Regulation 63
Show member pathways
 12.85 TP53 MYC ESR2 ESR1 CCND1 BRCA1
25
Relaxin signaling pathway 36
Show member pathways
 12.82 SRC PIK3CA PGR NCOA3 MTOR ESR2
26
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.81 SRC PIK3CA MTOR EGFR CCND1 AKT1
27
Immune response IL-23 signaling pathway 22
Show member pathways
 12.77 TP53 SRC PIK3CA MYC ERBB2 EGFR
28
ErbB signaling pathway 36 1
Show member pathways
 12.76 TP53 SRC PIK3CA MYC MTOR ERBB2
29
Notch Signaling Pathway (WikiPathways) 1
Show member pathways
 12.69 SRC MYC MTOR CCND1 AKT1
30
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.69 TP53 PIK3CA MTOR ERBB2 EGFR AKT1
31
VEGF Signaling 66
Show member pathways
 12.68 TP53 PIK3CA MYC MTOR EGFR AKT1
32
MicroRNAs in cancer 36
12.65 TP53 PIK3CA MYC MTOR MIR125A ERBB2
33
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.64 TP53 PIK3CA MTOR CCND1 AKT1
34
JAK-STAT signaling pathway 36
Show member pathways
 12.64 SRC PIK3CA MYC MTOR EGFR CCND1
35
Apoptosis Pathway 70
Show member pathways
 12.63 TP53 PIK3CA MTOR ERBB2 EGFR AKT1
36
Shigellosis 36
12.58 TP53 SRC PIK3CA MTOR EGFR AKT1
37
Development IGF-1 receptor signaling 22
Show member pathways
 12.58 TP53 PIK3CA MYC MTOR CCND1 AKT1
38
Prolactin Signaling Pathway 36 1
Show member pathways
 12.58 SRC PIK3CA MYC MTOR ESR2 ESR1
39
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.56 SRC PIK3CA ESR1 BRCA1 AKT1
40
Phospholipase D signaling pathway 36
Show member pathways
 12.51 PIK3CA MTOR EGFR AKT1
41
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.51 SRC PIK3CA MTOR ERBB2 EGFR
42
Human T-cell leukemia virus 1 infection 36
12.5 TP53 PIK3CA MYC CCND1 AKT1
43
DNA Damage Response 1
Show member pathways
 12.49 TP53 MYC CCND1 BRCA1
44
Development A3 receptor signaling 22
Show member pathways
 12.49 SRC PIK3CA MYC CCND1 AKT1
45
Development EGFR signaling pathway 22
Show member pathways
 12.49 SRC PIK3CA MYC ERBB2 EGFR AKT1
46
Signaling by ERBB2 65
Show member pathways
 12.48 SRC PIK3CA ERBB2 EGFR AKT1
47
Oocyte meiosis 36
Show member pathways
 12.47 PIK3CA PGR AR AKT1
48
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.47 TP53 SRC MTOR EGFR AKT1
49
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.46 PIK3CA NCOA3 ESR2 ESR1 ERBB2 EGFR
50
Viral carcinogenesis 36
12.42 TP53 SRC PIK3CA CCND1
Sources

GO Terms for Estrogen-Receptor Positive Breast Cancer

About this section

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.24 TP53 SRC PIK3CA PGR NCOA3 MYC
2 nucleus GO:0005634 10.22 TP53 SRC PGR NCOA3 MYC MTOR
3 nucleoplasm GO:0005654 10.07 TP53 PGR NCOA3 MYC MTOR HSPB8
4 nuclear chromatin GO:0000790 9.76 TP53 PGR NCOA3 MYC FOXA1 ESR2
5 host cell nucleus GO:0042025 9.43 PGR MYC ESR2 ESR1 CCND1 AR
6 protein-containing complex GO:0032991 9.28 TP53 NCOA3 MYC MTOR ESR1 EGFR

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.29 TP53 PGR NCOA3 MYC FOXA1 ESR2
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.17 TP53 MYC FOXA1 ESR2 ESR1 CCND1
3 phosphorylation GO:0016310 10.16 SRC PIK3CA MTOR ERBB2 EGFR AKT1
4 regulation of transcription by RNA polymerase II GO:0006357 10.16 TP53 MYC FOXA1 ESR1 ERBB2 EGFR
5 cellular response to DNA damage stimulus GO:0006974 10.13 TP53 MYC CCND1 BRCA1 AKT1
6 positive regulation of cell proliferation GO:0008284 10.13 MYC ERBB2 EGFR CCND1 AR AKT1
7 positive regulation of transcription by RNA polymerase II GO:0045944 10.07 TP53 PGR NCOA3 MYC FOXA1 ESR1
8 protein phosphorylation GO:0006468 10.06 SRC PIK3CA MTOR HSPB8 ERBB2 EGFR
9 cytokine-mediated signaling pathway GO:0019221 10.04 TP53 PIK3CA MYC CCND1 AKT1
10 protein deubiquitination GO:0016579 10.02 TP53 MYC ESR1 BRCA1 AR
11 regulation of cell proliferation GO:0042127 10.01 TP53 SRC EGFR BRCA1
12 negative regulation of gene expression GO:0010629 10.01 TP53 PGR MYC MIR125A ESR1 AKT1
13 positive regulation of protein phosphorylation GO:0001934 10 MTOR ERBB2 EGFR CCND1 AKT1
14 transcription initiation from RNA polymerase II promoter GO:0006367 9.98 PGR ESR2 ESR1 CCND1 AR
15 protein autophosphorylation GO:0046777 9.97 SRC MTOR ERBB2 EGFR AKT1
16 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 FOXA1 ESR2 ESR1 AKT1
17 positive regulation of translation GO:0045727 9.9 MYC MTOR ERBB2
18 cellular response to growth factor stimulus GO:0071363 9.89 ERBB2 EGFR AKT1
19 cellular response to drug GO:0035690 9.89 TP53 MYC EGFR
20 cellular response to hypoxia GO:0071456 9.89 TP53 SRC MYC MTOR AKT1
21 response to estrogen GO:0043627 9.88 ESR1 CCND1 BRCA1
22 positive regulation of MAP kinase activity GO:0043406 9.88 SRC ERBB2 EGFR
23 glucose metabolic process GO:0006006 9.87 PIK3CA MYC AKT1
24 steroid hormone mediated signaling pathway GO:0043401 9.87 PGR ESR1 AR
25 positive regulation of epithelial cell proliferation GO:0050679 9.87 MYC ERBB2 EGFR CCND1
26 T cell costimulation GO:0031295 9.85 SRC PIK3CA AKT1
27 positive regulation of fibroblast proliferation GO:0048146 9.85 MYC ESR1 EGFR
28 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.85 EGFR CCND1 AKT1
29 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 MYC MTOR EGFR AKT1
30 cellular response to reactive oxygen species GO:0034614 9.84 SRC EGFR AKT1
31 cellular response to estradiol stimulus GO:0071392 9.84 NCOA3 ESR1 EGFR
32 phosphatidylinositol 3-kinase signaling GO:0014065 9.83 PIK3CA ERBB2 AKT1
33 androgen receptor signaling pathway GO:0030521 9.83 NCOA3 BRCA1 AR
34 liver regeneration GO:0097421 9.81 MYC EGFR CCND1
35 activation of protein kinase B activity GO:0032148 9.81 SRC MTOR AKT1
36 epidermal growth factor receptor signaling pathway GO:0007173 9.81 SRC PIK3CA EGFR AKT1
37 positive regulation of protein kinase B signaling GO:0051897 9.8 SRC PIK3CA MTOR ESR1 ERBB2 EGFR
38 mammary gland alveolus development GO:0060749 9.79 ESR1 CCND1 AR
39 uterus development GO:0060065 9.78 SRC ESR1 CYP19A1
40 cellular response to epidermal growth factor stimulus GO:0071364 9.78 MYC ERBB2 EGFR AKT1
41 negative regulation of macroautophagy GO:0016242 9.77 PIK3CA MTOR AKT1
42 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 TP53 EGFR
43 negative regulation of telomerase activity GO:0051974 9.73 TP53 SRC
44 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.73 TP53 ESR1
45 Leydig cell differentiation GO:0033327 9.73 CCND1 AR
46 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.73 TP53 ESR1
47 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.73 SRC EGFR CCND1 AKT1
48 positive regulation of transcription by RNA polymerase III GO:0045945 9.72 MTOR AR
49 negative regulation of cell size GO:0045792 9.72 MTOR AKT1
50 positive regulation of glucose metabolic process GO:0010907 9.72 SRC AKT1

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.22 SRC PIK3CA NCOA3 MTOR ERBB2 EGFR
2 DNA-binding transcription factor activity GO:0003700 10.11 TP53 PGR MYC FOXA1 ESR2 ESR1
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.1 TP53 PGR NCOA3 MYC FOXA1 ESR2
4 zinc ion binding GO:0008270 10.08 TP53 PGR ESR2 ESR1 BRCA1 AR
5 kinase activity GO:0016301 10.08 SRC PIK3CA MTOR ERBB2 EGFR CCND1
6 sequence-specific DNA binding GO:0043565 10.07 PGR MYC FOXA1 ESR2 ESR1 AR
7 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 10.07 TP53 PGR MYC FOXA1 ESR2 ESR1
8 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 10.02 TP53 PGR MYC FOXA1 ESR1 AR
9 protein kinase activity GO:0004672 10.02 SRC MTOR HSPB8 ERBB2 EGFR CCND1
10 identical protein binding GO:0042802 10.02 TP53 PGR MTOR HSPB8 ESR2 ESR1
11 chromatin binding GO:0003682 10 TP53 FOXA1 ESR1 EGFR AR
12 transcription factor binding GO:0008134 9.99 TP53 MYC FOXA1 ESR1 CCND1 AR
13 protein-containing complex binding GO:0044877 9.98 SRC MYC MTOR EGFR CCND1
14 protein kinase binding GO:0019901 9.95 TP53 SRC MTOR ESR1 EGFR CCND1
15 transcription regulatory region DNA binding GO:0044212 9.91 TP53 FOXA1 BRCA1 AR
16 steroid hormone receptor activity GO:0003707 9.76 PGR ESR2 ESR1 AR
17 nuclear receptor activity GO:0004879 9.73 PGR ESR2 ESR1 AR
18 estrogen receptor activity GO:0030284 9.58 ESR2 ESR1
19 estrogen response element binding GO:0034056 9.56 ESR2 ESR1
20 steroid binding GO:0005496 9.56 PGR ESR2 ESR1 AR
21 ATPase binding GO:0051117 9.55 SRC PGR ESR1 EGFR AR
22 nitric-oxide synthase regulator activity GO:0030235 9.54 ESR1 EGFR AKT1
23 repressing transcription factor binding GO:0070491 9.35 PGR MYC ESR2 ESR1 AR
24 enzyme binding GO:0019899 9.32 TP53 SRC PGR ESR2 ESR1 EGFR
Sources

Sources for Estrogen-Receptor Positive Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....